Myeloma NZ

The addition of elotuzumab (Empliciti) to pomalidomide (Pomalyst) and dexamethasone cut the risk of disease progression or death by 46% compared...

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results...

Administering carfilzomib once a week significantly improves progression-free survival (PFS) and toxicity compared with twice a week among patients...

CHICAGO (Reuters) - Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a...

CHICAGO: Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before...

When diagnosing patients with multiple myeloma, it is important to identify the specific stage, mutations and risk level of the disease to determine...

CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Dr Rob Weinkove spoke at our patient seminar on CAR T-Cell Therapy: a New Frontier in...

Take a look at the International Myeloma Foundation's Newsletter, the Myeloma Minute  

A Kiwi dad who's dying of lung cancer has been bypassing the Pharmac system to get cheap pharmaceuticals directly from India - and says thousands of...